C. Sauter

M. Perales, P. Armand, C. Sauter, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Reprint of: Fast Cars and No Brakes: Autologous Stem Cell Transplantation as a Platform for Novel Immunotherapies.

M. Perales, P. Armand, C. Sauter, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

CD19-Targeted T Cells for Hematologic Malignancies: Clinical Experience to Date

R. Brentjens, C. Sauter, M. Davila, 2015, Cancer journal.

Early experience using salvage radiotherapy for relapsed/refractory non‐Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T cell therapy

M. Perales, M. Sadelain, B. Imber, 2020, British journal of haematology.

Efficacy and safety of CD19-targeted 19-28z CAR modified T cells in adult patients with relapsed or refractory B-ALL.

M. Sadelain, K. Curran, R. Brentjens, 2015 .

CD19-Targeted 19-28z CAR Modified Autologous T Cells Induce High Rates of Complete Remission and Durable Responses in Adult Patients with Relapsed, Refractory B-Cell ALL

M. Sadelain, K. Curran, R. Brentjens, 2014 .

Long‐Term Follow‐up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia

Mithat Gonen, Michel Sadelain, Xiuyan Wang, 2018, The New England journal of medicine.

Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management.

M. Perales, S. Devlin, R. Brentjens, 2020, Blood advances.

CAR T Cells for Mantle Cell Lymphoma: Is it Time to Reshuffle the Deck?

R. Brentjens, C. Sauter, 2020, Cancer cell.

Safety and feasibility of chimeric antigen receptor T cell therapy after allogeneic hematopoietic cell transplantation in relapsed/ refractory B cell non-Hodgkin lymphoma

M. Perales, S. Giralt, T. Jain, 2019, Leukemia.

Ex Vivo CD34+-Selected T Cell-Depleted Peripheral Blood Stem Cell Grafts for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Leukemia and Myelodysplastic Syndrome Is Associated with Low Incidence of Acute and Chronic Graft-versus-Host Disease and High Treatment Response.

J. Goldberg, M. Perales, M. V. D. van den Brink, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndrome: Comparison of Outcomes between CD34+ Selected and Unmodified Hematopoietic Stem Cell Transplantation.

M. Perales, S. Devlin, B. Andersson, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A novel reduced-intensity conditioning regimen induces a high incidence of sustained donor-derived neutrophil and platelet engraftment after double-unit cord blood transplantation.

J. Goldberg, M. Perales, S. Devlin, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Pentostatin in chronic lymphocytic leukemia

M. Weiss, N. Lamanna, C. Sauter, 2008, Expert opinion on drug metabolism & toxicology.

Geriatric syndromes in 2-year, progression-free survivors among older recipients of allogeneic hematopoietic cell transplantation

M. Perales, A. Shahrokni, R. Baser, 2020, Bone Marrow Transplantation.

Reconstitution of the gut microbiota of antibiotic-treated patients by autologous fecal microbiota transplant

E. Robilotti, Cesar J. Figueroa, S. Morjaria, 2018, Science Translational Medicine.

Low-dose unfractionated heparin prophylaxis is a safe strategy for the prevention of hepatic sinusoidal obstruction syndrome after myeloablative adult allogenic stem cell transplant

J. Goldberg, M. Perales, S. Devlin, 2022, Bone Marrow Transplantation.

Baseline and interim functional imaging with PET effectively risk stratifies patients with peripheral T-cell lymphoma.

S. Horwitz, H. Schöder, N. Mehta-Shah, 2019, Blood advances.

Non-myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Adults with Relapsed and Refractory Mantle Cell Lymphoma: A Single Center Analysis in the Rituximab Era

A. Zelenetz, M. Perales, S. Devlin, 2015, Bone Marrow Transplantation.

PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study.

A. Zelenetz, N. Shukla, M. Perales, 2015, The Lancet. Oncology.

Outcomes of Autologous Hematopoietic Cell Transplantation in Older Patients with Diffuse Large B Cell Lymphoma.

F. Awan, A. Goodman, F. Locke, 2022, Transplantation and cellular therapy.

Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristics

N. Schmitz, S. Montoto, D. Blaise, 2021, Blood advances.

Autologous and Allogeneic Hematopoietic Cell Transplantation for Diffuse Large B-cell Lymphoma-Type Richter Syndrome.

C. Jacobson, Q. Bashir, Z. DeFilipp, 2021, Blood advances.

Is Autologous Transplant in Relapsed DLBCL Patients Achieving Only a PET+ PR Appropriate in the CAR-T cell Era?

K. Ahn, N. Shah, M. Hamadani, 2020, Blood.

The potential benefit of allogeneic over autologous transplantation in patients with very early relapsed and refractory follicular lymphoma with prior remission duration of ≤12 months

A. Zelenetz, M. Perales, S. Devlin, 2016, British journal of haematology.

Evaluation of Melphalan Exposure in Lymphoma Patients Undergoing BEAM and Autologous Hematopoietic Cell Transplant.

M. Perales, S. Devlin, S. Giralt, 2022, Transplantation and cellular therapy.

Highly favorable outcomes with salvage radiation therapy and autologous hematopoietic cell transplantation in relapsed and refractory DLBCL patients with minimal to no response to salvage chemotherapy

J. Yahalom, K. Chau, M. Scordo, 2022, Bone Marrow Transplantation.

Reduced-intensity conditioning hematopoietic stem cell transplantation for chronic lymphocytic leukemia and Richter's transformation.

A. Zelenetz, M. Perales, S. Devlin, 2021, Blood advances.

Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies.

A. Zelenetz, M. Perales, S. Devlin, 2020, Blood advances.

Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma.

A. Zelenetz, M. Perales, M. Fleisher, 2017, Blood.

Strategies to improve outcomes of autologous hematopoietic cell transplant in lymphoma

H. Lazarus, S. Giralt, C. Sauter, 2018, Bone Marrow Transplantation.

Vitamin D Insufficiency and Clinical Outcomes with Chimeric Antigen Receptor T-Cell Therapy in Large B-cell Lymphoma: Vitamin D insufficiency and CAR-T in LBCL.

G. Salles, M. Perales, S. Devlin, 2022, Transplantation and cellular therapy.

Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma

S. Seo, M. Perales, S. Devlin, 2020, Blood Cancer Journal.

Outcomes of hematopoietic cell transplantation for diffuse large B cell lymphoma transformed from follicular lymphoma.

J. Vose, M. Aljurf, R. Gale, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Pretransplantation fluorine-18-deoxyglucose--positron emission tomography scan lacks prognostic value in chemosensitive B cell non-hodgkin lymphoma patients undergoing nonmyeloablative allogeneic stem cell transplantation.

S. Devlin, Junting Zheng, C. Moskowitz, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A prospective study of an alemtuzumab containing reduced-intensity allogeneic stem cell transplant program in patients with poor-risk and advanced lymphoid malignancies

M. Perales, James W. Young, S. Giralt, 2014, Leukemia & lymphoma.

Pre-Transplant FDG-PET Scan Lacks Prognostic Value in Chemosensitive B-Cell Non-Hodgkin Lymphoma Patients Undergoing Non-Myeloablative Allogeneic Stem Cell Transplantation.

J. Goldberg, M. Perales, W. Cohen-Levy, 2012 .

Imbalanced immune response and dysregulation of neural functions underline fatal opportunistic encephalitis caused by astrovirus

K. Wollenberg, A. Nath, M. Weller, 2022, bioRxiv.

The prognostic impact of peripheral blood progenitor cell dose following high-dose therapy and autologous stem cell transplant for hematologic malignancies

S. Giralt, C. Sauter, 2015, Leukemia & lymphoma.

Oral Proteasome Inhibitor Ixazomib for Switch-Maintenance Prophylaxis of Recurrent or Late Acute and Chronic Graft-versus-Host Disease after Day 100 in Allogeneic Stem Cell Transplantation.

M. Perales, S. Devlin, S. Giralt, 2021, Transplantation and cellular therapy.

R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma.

D. Correa, L. Deangelis, A. Omuro, 2015, Blood.

Allogeneic haematopoietic cell transplant in patients with relapsed/refractory anaplastic large cell lymphoma

M. Perales, K. Ahn, J. Zain, 2022, British journal of haematology.

Ex Vivo T Cell-Depleted Hematopoietic Stem Cell Transplantation for Adult Patients with Acute Myeloid Leukemia in First and Second Remission: Long-Term Disease-Free Survival with a Significantly Reduced Risk of Graft-versus-Host Disease.

M. Perales, James W. Young, S. Giralt, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

High progression-free survival after intermediate intensity double unit cord blood transplantation in adults.

M. Perales, S. Devlin, K. Hsu, 2020, Blood advances.

Lifting the mantle: Unveiling new treatment approaches in relapsed or refractory mantle cell lymphoma.

M. Perales, Anita Kumar, C. Sauter, 2015, Blood reviews.

Toxicities of high-dose chemotherapy and autologous hematopoietic cell transplantation in older patients with lymphoma.

M. Perales, S. Devlin, C. Rondon-Clavo, 2021, Blood advances.

C. Sauter, J. Barker, 2008, Current opinion in hematology.

Engraftment Kinetics after Transplantation of Double Unit Cord Blood Grafts Combined with Haplo-identical CD34+ Cells without Anti-thymocyte Globulin

M. Arcila, M. Perales, S. Devlin, 2020, Leukemia.

Use of anti-thymocyte globulin (ATG) for the treatment of pure red cell aplasia and immune-mediated cytopenias after allogeneic hematopoietic cell transplantation: a case series

M. Perales, S. Giralt, A. Jakubowski, 2020, Bone Marrow Transplantation.

Noninvasive Monitoring of Mantle Cell Lymphoma by Immunoglobulin Gene Next-Generation Sequencing in a Phase 2 Study of Sequential Chemoradioimmunotherapy Followed by Autologous Stem-Cell Rescue

T. Willis, M. Faham, K. Kong, 2021, Clinical lymphoma, myeloma & leukemia.

Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma

M. Perales, A. Nagler, S. Devlin, 2022, Leukemia.

Impact of allogeneic hematopoietic cell transplantation on immune evasive mechanisms in relapsed refractory large B-cell lymphoma

M. Perales, S. Devlin, H. Schöder, 2020, Bone Marrow Transplantation.

Hematopoietic-cell transplantation for lymphoma in the era of genetically engineered cellular therapy: it's not quite time to scrap the old vehicle for the new car.

M. Scordo, C. Sauter, R. Lin, 2019, Current opinion in hematology.

CD34+ -selected hematopoietic stem cell transplant conditioned with a myeloablative regimen in patients with advanced myelofibrosis

M. Perales, S. Devlin, S. Giralt, 2022, Bone Marrow Transplantation.

Improved GRFS after posttransplant cyclophosphamide-based vs ATG-based HLA-mismatched unrelated donor transplant

M. Perales, S. Devlin, L. Lekakis, 2022, Blood advances.

Low dose Unfractionated Heparin Prophylaxis is a Safe Strategy for the Prevention of Hepatic Sinusoidal Obstruction Syndrome After Myeloablative Adult Allogenic Stem Cell Transplant

J. Goldberg, M. Perales, S. Devlin, 2022, Bone Marrow Transplantation.

High Disease-Free Survival and Enhanced Protection Against Relapse after Double-Unit Cord Blood Transplantation (DCB-T) When Compared to Unrelated Donor Transplantation (URD-T) in Patients with Acute Leukemia, MDS and CML

J. Goldberg, M. Perales, S. Devlin, 2014 .

Impact of geriatric vulnerabilities on allogeneic hematopoietic cell transplantation outcomes in older patients with hematologic malignancies

M. Perales, A. Shahrokni, S. Devlin, 2019, Bone Marrow Transplantation.

The Hematopoietic Cell Transplant-Co-Morbidity Index (HCT-CI) Predicts Outcomes After T Cell Depleted (TCD) Allogeneic HCT For AML and MDS

J. Goldberg, M. Perales, S. Devlin, 2013 .

ASBMT Statement on Routine Prophylaxis for Central Nervous System Recurrence of Acute Lymphoblastic Leukemia following Allogeneic Hematopoietic Cell Transplantation.

M. Perales, A. Nagler, Z. DeFilipp, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Characteristics and Impact of Post-Transplant Interdisciplinary Palliative Care Consultation in Older Allogeneic Hematopoietic Cell Transplant Recipients.

M. Perales, S. Devlin, J. Nelson, 2020, Journal of palliative medicine.

Racial disparities in access to alternative donor allografts persist in the era of “donors for all”

M. Perales, James W. Young, A. Scaradavou, 2021, Blood advances.

ASBMT Practice Guidelines Committee Survey on Long-Term Follow-Up Clinics for Hematopoietic Cell Transplant Survivors.

M. Perales, A. Nagler, M. Mohty, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation.

N. E. Babady, Yeon Joo Lee, G. Papanicolaou, 2020, The Journal of clinical investigation.

Sirolimus, tacrolimus and low-dose methotrexate based graft-versus-host disease prophylaxis after non-ablative or reduced intensity conditioning in related and unrelated donor allogeneic hematopoietic cell transplant

J. Goldberg, M. Perales, S. Devlin, 2015, Leukemia & lymphoma.

Serious infection risk and immune recovery after double-unit cord blood transplantation without antithymocyte globulin.

G. Papanicolaou, M. Perales, M. V. D. van den Brink, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

T Cell Depletion as an Alternative Approach for Patients 55 Years or Older Undergoing Allogeneic Stem Cell Transplantation as Curative Therapy for Hematologic Malignancies.

J. Goldberg, M. Perales, James W. Young, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Incidence, nature and mortality of cytomegalovirus infection after double-unit cord blood transplant

G. Papanicolaou, M. Perales, S. Devlin, 2015, Leukemia & lymphoma.

A retrospective analysis of peripheral T-cell lymphoma treated with the intention to transplant in the first remission.

A. Zelenetz, J. Goldberg, S. Horwitz, 2013, Clinical lymphoma, myeloma & leukemia.

Durable Remission Following “Off-the-Shelf” Chimeric Antigen Receptor (CAR) T-Cells in Patients with Relapse/Refractory (R/R) B-Cell Malignancies

M. Perales, M. Sadelain, K. Curran, 2020 .

Chimeric Antigen Receptor T-Cell Therapy.

R. Carlson, E. Shpall, T. Fry, 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

CD34-Selected Hematopoietic Stem Cell Transplants Conditioned with Myeloablative Regimens and Antithymocyte Globulin for Advanced Myelodysplastic Syndrome: Limited Graft-versus-Host Disease without Increased Relapse.

J. Goldberg, M. Perales, S. Devlin, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Toxicity and Response following CD19-specific CAR T cells in pediatric/young adult relapsed/refractory B-ALL.

David A. Williams, L. Silverman, N. Shukla, 2019, Blood.

Fecal microbiota diversity disruption and clinical outcomes after auto-HCT: a multicenter observational study.

Y. Taur, A. Bush, E. Pamer, 2020, Blood.

Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.

C. Brennan, N. Schultz, A. Viale, 2017, Cancer discovery.

Autologous stem cell transplant in recurrent or refractory primary or secondary central nervous system lymphoma using thiotepa, busulfan and cyclophosphamide

A. Omuro, M. Matasar, C. Moskowitz, 2015, Leukemia & lymphoma.

Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant.

P. Riedell, F. Awan, M. Krem, 2021, JAMA oncology.

Distinctive Infectious Complications in Patients with Central Nervous System Lymphoma Undergoing Thiotepa, Busulfan, and Cyclophosphamide-conditioned Autologous Stem Cell Transplantation.

L. Deangelis, S. Morjaria, Y. Taur, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A Comprehensive Assessment of Toxicities in Patients with Central Nervous System Lymphoma Undergoing Autologous Stem Cell Transplantation Using Thiotepa, Busulfan, and Cyclophosphamide Conditioning.

L. Deangelis, A. Omuro, S. Giralt, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Rituximab, methotrexate (MTX), procarbazine, and vincristine (R-MPV) followed by consolidation high-dose chemotherapy (HDC) and autologous stem-cell transplant (ASCT) for newly diagnosed primary CNS lymphoma (PCNSL).

D. Correa, L. Deangelis, A. Omuro, 2012 .

EXABS-213-CT DEBATE: CAR T-Cell or Autologous Stem Cell Transplantation (ASCT) for Relapsed LBCL-Pro ASCT.

C. Sauter, 2022, Clinical lymphoma, myeloma & leukemia.

Modified SMILE (mSMILE) and intensity-modulated radiotherapy (IMRT) for extranodal NK-T lymphoma nasal type in a single-center population

V. Seshan, S. Horwitz, M. Lunning, 2020, Leukemia & lymphoma.

Outcomes of primary refractory diffuse large B‐cell lymphoma (DLBCL) treated with salvage chemotherapy and intention to transplant in the rituximab era

A. Zelenetz, Zhigang Zhang, K. Woo, 2017, British journal of haematology.

Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplant.

J. Teruya-Feldstein, M. Arcila, M. Perales, 2020, The Journal of clinical investigation.

Short-term weekly chemotherapy followed by high-dose therapy with autologous bone marrow transplantation for lymphoblastic and Burkitt's lymphomas in adult patients.

R. Stahel, C. Dommann-Scherrer, L. Jost, 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

High Disease-Free Survival with Enhanced Protection against Relapse after Double-Unit Cord Blood Transplantation When Compared with T Cell-Depleted Unrelated Donor Transplantation in Patients with Acute Leukemia and Chronic Myelogenous Leukemia.

M. Perales, M. V. D. van den Brink, S. Devlin, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Double-Unit Cord Blood (CB) Transplantation (DCBT) Combined with Haplo-Identical Peripheral Blood CD34+ Cells (HaploCD34+) Is Associated with Enhanced Neutrophil Recovery, Universal Haplo Rejection, and Frequent Pre-Engraftment Syndrome

M. Perales, James W. Young, A. Scaradavou, 2015 .

Higher total body irradiation dose-intensity in fludarabine/TBI-based reduced-intensity conditioning regimen is associated with inferior survival in non-Hodgkin lymphoma patients undergoing allogeneic transplantation: Flu/2Gy TBI vs Flu/4Gy TBI in NHL.

F. Awan, K. Ahn, R. Karmali, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Hematopoietic Cell Transplantation is Feasible in Patients with Prior COVID-19 Infection

G. Papanicolaou, M. Kamboj, M. Perales, 2021, Transplantation and Cellular Therapy.

High day 28 ST2 levels predict for acute graft-versus-host disease and transplant-related mortality after cord blood transplantation.

J. Goldberg, M. Perales, R. Jenq, 2015, Blood.

EASIX score predicts inferior survival after allogeneic hematopoietic cell transplantation

M. Perales, S. Devlin, S. Giralt, 2023, Bone Marrow Transplantation.

Double-Unit Cord Blood (CB) Transplantation Combined with Haplo-Identical CD34+ Cells Results in 100% CB Engraftment with Enhanced Myeloid Recovery

J. Goldberg, M. Perales, S. Devlin, 2014 .

Double-Unit Cord Blood (CB) Transplantation Combined With Haplo-Identical CD34+ Cell-Selected PBSC Results In 100% CB Engraftment With Enhanced Myeloid Recovery

J. Goldberg, M. Perales, S. Devlin, 2013 .

Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy.

R. Larson, M. Perales, A. Nagler, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality.

M. Perales, S. Devlin, M. Palomba, 2020, Blood advances.

Dynamic EASIX scores closely predict nonrelapse mortality after allogeneic hematopoietic cell transplantation

M. Perales, S. Devlin, S. Giralt, 2019, Blood advances.

High-Dose Chemotherapy and Autologous Stem Cell Transplant in Older Patients with Lymphoma

P. Hamlin, O. Lahoud, C. Sauter, 2015, Current Oncology Reports.

Cellular therapies in acute lymphoblastic leukemia.

R. Brentjens, Jae H. Park, C. Sauter, 2011, Hematology/oncology clinics of North America.

Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes.

M. Perales, M. Doubrovin, R. O'reilly, 2010, Blood.

Impact of omitting post-transplant minidose-methotrexate doses in allogeneic hematopoietic cell transplantation

M. Perales, S. Devlin, S. Giralt, 2022, Leukemia & lymphoma.

Prognostic Value of FDG PET/CT before Allogeneic and Autologous Stem Cell Transplantation for Aggressive Lymphoma.

A. Zelenetz, M. Gönen, H. Schöder, 2015, Radiology.

Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma.

A. Zelenetz, H. Schoder, S. Devlin, 2015, Blood.

Outcomes of Relapsed and Refractory Primary Mediastinal (Thymic) Large B Cell Lymphoma Treated with Second-Line Therapy and Intent to Transplant.

A. Zelenetz, P. Hamlin, A. Ni, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A phase II study of a nonmyeloablative allogeneic stem cell transplant with peritransplant rituximab in patients with B cell lymphoid malignancies: favorably durable event-free survival in chemosensitive patients.

A. Zelenetz, J. Goldberg, M. Perales, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Development and Evaluation of a Human Single Chain Variable Fragment (scFv) Derived Bcma Targeted CAR T Cell Vector Leads to a High Objective Response Rate in Patients with Advanced MM

S. Almo, K. Curran, C. Liu, 2017 .

Development and validation of a disease risk stratification system for patients with haematological malignancies: a retrospective cohort study of the European Society for Blood and Marrow Transplantation registry.

S. Montoto, F. Baron, M. Perales, 2021, The Lancet. Haematology.

Allogeneic CAR-T PBCAR0191 with Intensified Lymphodepletion Is Highly Active in Patients with Relapsed/Refractory B-Cell Malignancies

C. Jacobson, N. Jain, L. Akard, 2021, Blood.

Preliminary safety and efficacy of PBCAR0191, an allogeneic, off-the-shelf CD19-targeting CAR-T product, in relapsed/refractory (r/r) CD19+ NHL.

C. Jacobson, N. Jain, L. Akard, 2021 .

Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma

F. Awan, M. Perales, C. Jacobson, 2022, Haematologica.

Autologous Transplant versus Chimeric Antigen Receptor T-cell Therapy for Relapsed DLBCL in Partial Remission.

C. Turtle, M. Pasquini, F. Locke, 2021, Blood.

The International Prognostic Index Is Associated with Outcomes in Diffuse Large B Cell Lymphoma after Chimeric Antigen Receptor T Cell Therapy.

M. Perales, S. Devlin, R. Shouval, 2021, Transplantation and cellular therapy.

Tolerance and effectiveness of recombinant interleukin-2 (r-met Hu IL-2 [ala-125]) and lymphokine-activated killer cells in patients with metastatic solid tumors.

R. Stahel, J. Sculier, J. Klastersky, 1989, European journal of cancer & clinical oncology.

Outcomes and Utilization Trends of Front-Line Autologous Hematopoietic Cell Transplantation for Mantle Cell Lymphoma.

P. Riedell, Sonali M. Smith, F. Locke, 2021, Transplantation and cellular therapy.

Allogeneic Hematopoietic Cell Transplantation After CAR T-cell Therapy in Large B-cell Lymphoma: Allogeneic-HCT after CAR T-cell therapy.

M. Perales, A. Nagler, S. Devlin, 2022, Transplantation and cellular therapy.

ASTCT, CIBMTR and EBMT Clinical Practice recommendations for transplant and cellular therapies in mantle cell lymphoma.

Michael L. Wang, Sonali M. Smith, J. Friedberg, 2021, Bone Marrow Transplantation.

Management of prolonged cytopenia following CAR T-cell therapy

M. Perales, S. Devlin, R. Shouval, 2022, Bone Marrow Transplantation.

Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP53 alterations

M. Perales, P. Hamlin, S. Giralt, 2018, British journal of haematology.

Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy

G. Salles, M. Perales, M. V. D. van den Brink, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma

Michael L. Wang, Sonali M. Smith, J. Friedberg, 2021, Transplantation and cellular therapy.

Clinical Responses and Pharmacokinetics of MCARH171, a Human-Derived Bcma Targeted CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma: Final Results of a Phase I Clinical Trial

A. Lesokhin, K. Curran, A. Jungbluth, 2018, Blood.

Longitudinal cognitive assessment in patients with primary CNS lymphoma treated with induction chemotherapy followed by reduced-dose whole-brain radiotherapy or autologous stem cell transplantation

D. Correa, L. Deangelis, A. Omuro, 2019, Journal of Neuro-Oncology.

Cellular Therapy During COVID-19: Lessons Learned and Preparing for Subsequent Waves

E. Robilotti, M. Kamboj, M. Perales, 2021, Transplantation and Cellular Therapy.

Burden and Impact of Toxicities on Outcomes for Aggressive B Cell Non-Hodgkin Lymphoma Patients after CD19-Directed Chimeric Antigen Receptor T Cell: Real-World Experience

M. Perales, S. Devlin, M. Palomba, 2020, Biology of Blood and Marrow Transplantation.

Outcomes of Allogeneic Hematopoietic Cell Transplantation in T-cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research.

J Wagner, F. Awan, M. Krem, 2022, Transplantation and cellular therapy.

Fractionated Infusion of Hematopoietic Progenitor Cells Does Not Improve Neutrophil Recovery or Survival in Allograft Recipients.

M. Perales, S. Devlin, James W. Young, 2021, Transplantation and cellular therapy.

Hematopoietic Cell Transplantation Comorbidity Index Predicts Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Receiving CD34+ Selected Grafts for Allogeneic Hematopoietic Cell Transplantation.

M. Perales, M. V. D. van den Brink, S. Devlin, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Favorable outcomes in elderly patients undergoing high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma.

A. Zelenetz, J. Goldberg, M. Perales, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL.

A. Zelenetz, H. Schoder, S. Devlin, 2018, Blood.

A Phase Ib/IIa Trial of the Combination of Romidepsin, Lenalidomide and Carfilzomib in Patients with Relapsed/Refractory Lymphoma Shows Complete Responses in Relapsed and Refractory T-Cell Lymphomas

A. Zelenetz, Laura H. Tang, S. Horwitz, 2016 .

The Simplified Comorbidity Index: a new tool for prediction of nonrelapse mortality in allo-HCT

M. Perales, M. V. D. van den Brink, A. Nagler, 2021, Blood advances.

Burden and impact of multifactorial geriatric syndromes in allogeneic hematopoietic cell transplantation for older adults.

M. Perales, A. Shahrokni, S. Giralt, 2019, Blood advances.

Impact of conditioning regimen intensity on the outcomes of peripheral T‐cell lymphoma, anaplastic large cell lymphoma and angioimmunoblastic T‐cell lymphoma patients undergoing allogeneic transplant

K. Ahn, M. Shadman, C. Cutler, 2022, British journal of haematology.

DEFINING PROGRESSION FREE SURVIVAL AFTER MULTIPLE LINES OF THERAPY AND IMPACT OF DYNAMIC CHANGES IN FLIPI FOR MULTIPLY RELAPSED FOLLICULAR LYMPHOMA IN THE RITUXIMAB ERA

V. Seshan, S. Horwitz, J. Gerecitano, 2017 .

Effect of time to relapse on overall survival in patients with mantle cell lymphoma following autologous haematopoietic cell transplantation

J. Vose, P. Riedell, Sonali M. Smith, 2021, British journal of haematology.

Outcomes of autologous hematopoietic cell transplantation in diffuse large B-cell lymphoma refractory to first line chemoimmunotherapy.

L. Costa, M. Hamadani, C. Sauter, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Efficacy of Donor and ‘Third Party’ (Tabelecleucel) EBV-Specific T Cells for Treatment of Central Nervous System (CNS) EBV-PTLD

James W. Young, H. Castro-Malaspina, R. O'reilly, 2019, Biology of Blood and Marrow Transplantation.

Impact and safety of chimeric antigen receptor T-cell therapy in older, vulnerable patients with relapsed/refractory large B-cell lymphoma

M. Perales, S. Devlin, P. Hamlin, 2020, Haematologica.

HIGHLY FAVORABLE OUTCOMES WITH RT FOLLOWED BY ASCT IN LOW/LOW‐INTERMEDIATE SECONDARY AGE ADJUSTED IPI REL/REF DLBCL PATIENTS REFRACTORY TO SALVAGE CHEMOTHERAPY

J. Yahalom, K. Chau, M. Scordo, 2019, Hematological Oncology.

Bridging Radiation Rapidly and Effectively Cytoreduces High Risk Relapsed/Refractory Aggressive B-Cell Lymphomas Prior to Chimeric Antigen Receptor T-Cell Therapy.

H. Schoder, M. Perales, S. Devlin, 2022, Transplantation and cellular therapy.

toxicities and long term survival after autologous hematopoietic stem cell transplantation for older patients with relapsed refractory hodgkin lymphoma

S. Devlin, P. Hamlin, S. Giralt, 2019 .

Implications of Minimal Residual Disease Negative Complete Remission (MRD-CR) and Allogeneic Stem Cell Transplant on Safety and Clinical Outcome of CD19-Targeted 19-28z CAR Modified T Cells in Adult Patients with Relapsed, Refractory B-Cell ALL

M. Sadelain, K. Curran, R. Brentjens, 2015 .

Multi-Center Clinical Trial of CAR T Cells in Pediatric/Young Adult Patients with Relapsed B-Cell ALL

L. Silverman, N. Shukla, M. Sadelain, 2015 .

Autologous hematopoietic cell transplantation in diffuse large B-cell lymphoma after three or more lines of prior therapy: evidence of durable benefit

K. Ahn, M. Kharfan-Dabaja, A. Herrera, 2022, Haematologica.

The geriatric syndrome of sarcopenia impacts allogeneic hematopoietic cell transplantation outcomes in older lymphoma patients

M. Perales, S. Devlin, H. Schöder, 2020, Leukemia & lymphoma.

Intervention Versus Observation: What Is the Appropriate Endpoint? Assessment of Endpoints in Patients with Advanced Stage Follicular Lymphoma Who Are Initially Observed

A. Zelenetz, S. Horwitz, A. Intlekofer, 2016 .

ASTCT Clinical practice recommendations for transplant and cellular therapies in diffuse large B-cell lymphoma.

F. Awan, M. Perales, L. Lekakis, 2023, Transplantation and cellular therapy.

CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results

A. Holodny, M. Perales, M. Sadelain, 2023, Nature Medicine.

NEURO/MEDICAL ONCOLOGY

Scott N. Hwang, Katrina H. Smith, Susan M. Chang, 2013 .

Third-party cytomegalovirus-specific T cells improved survival in refractory cytomegalovirus viremia after hematopoietic transplant

G. Papanicolaou, M. Perales, Jinjuan Yao, 2023, The Journal of Clinical Investigation.

Validation of the CIBMTR scoring system in predicting early relapse of multiple myeloma after autologous hematopoietic cell transplant.

C. Sauter, Louis Williams, F. Anwer, 2022, Bone marrow transplantation.

Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma

C. Brennan, N. Schultz, D. Louis, 2017, Neuro-oncology.

A Phase II Study of Prophylactic Anakinra to Prevent CRS and Neurotoxicity in Patients Receiving CD19 CAR T Cell Therapy for Relapsed or Refractory Lymphoma

M. Perales, M. Sadelain, R. Brentjens, 2021, Blood.

Loss of Microbiota Diversity after Autologous Stem Cell Transplant Is Comparable to Injury in Allogeneic Stem Cell Transplant

E. Pamer, M. Perales, R. Jenq, 2018, Blood.

Siltuximab for First-Line Treatment of Cytokine Release Syndrome: A Response to the National Shortage of Tocilizumab

M. Kalaycio, B. Hill, B. Pohlman, 2022, Blood.

Preliminary Safety and Efficacy of PBCAR0191, an Allogeneic 'Off-the-Shelf' CD19-Directed CAR-T for Patients with Relapsed/Refractory (R/R) CD19+ B-ALL

H. Kantarjian, N. Jain, B. Shah, 2021, Blood.

Impact of thiotepa dose-intensity in primary diffuse large B-cell lymphoma of the central nervous system undergoing autologous hematopoietic cell transplant with thiotepa/carmustine conditioning.

F. Awan, K. Ahn, M. Scordo, 2023, Bone marrow transplantation.

Allogeneic Transplantation for Chronic Myelomonocytic Leukemia (CMML) Is Associated with High Disease-Free Survival Even in the Setting of High-Risk Disease

W. Shi, S. Devlin, S. Giralt, 2014 .

Interim PET Evaluation By Deauville Criteria Is an Effective Risk Stratification Tool in PTCL

S. Horwitz, H. Schöder, N. Mehta-Shah, 2016 .

Pilot Study of Telehealth Evaluations in Patients Undergoing Hematopoietic Cell Transplantation.

S. Giralt, H. Landau, M. Scordo, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

MSKCC EARLY EXPERIENCE USING RADIOTHERAPY AS A BRIDGING STRATEGY FOR RELAPSED DIFFUSE LARGE B CELL LYMPHOMA BEFORE CD19 CAR T THERAPY

M. Perales, M. Sadelain, B. Imber, 2019, Blood.

Outcomes of adult T-Cell leukemia/lymphoma with allogeneic stem cell transplantation: single-institution experience

H. Schoder, M. Perales, S. Horwitz, 2021, Leukemia & lymphoma.

Validation of the CIBMTR scoring system in predicting early relapse of multiple myeloma after autologous hematopoietic cell transplant

C. Sauter, Louis Williams, F. Anwer, 2023, Bone Marrow Transplantation.

Utility of routine pulmonary function test after autologous hematopoietic cell transplantation in lymphoma.

M. Perales, S. Devlin, S. Giralt, 2023, Leukemia & lymphoma.

Safety and feasibility of chimeric antigen receptor T cell therapy after allogeneic hematopoietic cell transplantation in relapsed/ refractory B cell non-Hodgkin lymphoma

M. Perales, S. Giralt, T. Jain, 2019, Leukemia.

Non-myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Adults with Relapsed and Refractory Mantle Cell Lymphoma: A Single Center Analysis in the Rituximab Era

A. Zelenetz, M. Perales, S. Devlin, 2015, Bone Marrow Transplantation.

Reduced Intensity Compared to Non-myeloablative Conditioning in Patients with Non-Hodgkin Lymphoma undergoing Allogeneic Hematopoietic Stem Cell Transplantation.

M. Perales, S. Devlin, A. Jakubowski, 2023, Transplantation and cellular therapy.

Modi ﬁ ed EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells

M. Perales, R. Brentjens, R. Shouval, 2021 .

Baseline and interim functional imaging with PET effectively risk stratifies patients with peripheral T-cell lymphoma.

S. Horwitz, H. Schöder, N. Mehta-Shah, 2019, Blood advances.

Open-label pilot study of romiplostim for thrombocytopenia after autologous hematopoietic cell transplantation

M. Perales, S. Devlin, G. Soff, 2022, Blood advances.

Reconstitution of the gut microbiota of antibiotic-treated patients by autologous fecal microbiota transplant

E. Robilotti, Cesar J. Figueroa, S. Morjaria, 2018, Science Translational Medicine.

Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission

C. Turtle, P. Reagan, P. Hematti, 2022 .

M. Perales, M. V. D. van den Brink, S. Devlin, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.